Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLI NASDAQ:LUCD NASDAQ:PROF NASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/ALUCDLucid Diagnostics$1.03-3.7%$1.11$0.73▼$1.80$116.07M1.241.51 million shs1.30 million shsPROFProfound Medical$4.04+2.0%$5.15$3.76▼$9.17$119.28M0.55178,170 shs61,898 shsRCELAvita Medical$4.56+4.1%$5.10$3.60▼$14.16$116.59M1.58272,155 shs293,334 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%0.00%LUCDLucid Diagnostics-3.74%-24.82%+4.98%-20.16%+23.92%PROFProfound Medical+2.02%-1.94%-25.87%-38.23%-49.18%RCELAvita Medical+4.11%+7.04%-20.83%-17.69%-52.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/ALUCDLucid Diagnostics$1.03-3.7%$1.11$0.73▼$1.80$116.07M1.241.51 million shs1.30 million shsPROFProfound Medical$4.04+2.0%$5.15$3.76▼$9.17$119.28M0.55178,170 shs61,898 shsRCELAvita Medical$4.56+4.1%$5.10$3.60▼$14.16$116.59M1.58272,155 shs293,334 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%0.00%LUCDLucid Diagnostics-3.74%-24.82%+4.98%-20.16%+23.92%PROFProfound Medical+2.02%-1.94%-25.87%-38.23%-49.18%RCELAvita Medical+4.11%+7.04%-20.83%-17.69%-52.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/ALUCDLucid Diagnostics 3.00Buy$3.65254.37% UpsidePROFProfound Medical 3.00Buy$11.00172.28% UpsideRCELAvita Medical 2.40Hold$11.60154.39% UpsideCurrent Analyst Ratings BreakdownLatest AKLI, LUCD, PROF, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025LUCDLucid DiagnosticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.00 ➝ $2.509/5/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $14.008/13/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/11/2025RCELAvita MedicalLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$14.00 ➝ $8.008/8/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $18.008/8/2025RCELAvita MedicalBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeNeutral ➝ Sell$3.007/16/2025LUCDLucid DiagnosticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58LUCDLucid Diagnostics$4.35M25.69N/AN/A($0.78) per share-1.32PROFProfound Medical$11.84M10.28N/AN/A$2.01 per share2.01RCELAvita Medical$74.88M1.62N/AN/A$0.17 per share26.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/ALUCDLucid Diagnostics-$45.53M-$1.19N/AN/AN/A-1,476.35%N/A-120.43%11/12/2025 (Estimated)PROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/6/2025 (Estimated)RCELAvita Medical-$61.85M-$1.97N/AN/AN/A-68.87%-632.62%-71.52%11/6/2025 (Estimated)Latest AKLI, LUCD, PROF, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/7/2025Q2 2025RCELAvita Medical-$0.26-$0.38-$0.12-$0.38$34.27 million$18.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80LUCDLucid DiagnosticsN/A1.151.13PROFProfound Medical0.118.537.07RCELAvita Medical9.390.580.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%LUCDLucid Diagnostics74.01%PROFProfound Medical47.86%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipAKLIAkili10.10%LUCDLucid Diagnostics6.80%PROFProfound Medical1.52%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionOptionableLUCDLucid Diagnostics70108.48 million101.10 millionNo DataPROFProfound Medical15030.12 million29.66 millionOptionableRCELAvita Medical13026.62 million25.87 millionOptionableAKLI, LUCD, PROF, and RCEL HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL5 hours ago | prnewswire.comRCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law FirmSeptember 11 at 3:31 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCELSeptember 10 at 3:03 PM | globenewswire.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comRCEL Alert: Kirby McInerney LLP Encourages AVITA Medical, Inc. Investors to Inquire about InvestigationSeptember 9, 2025 | businesswire.comAVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 8, 2025 | seekingalpha.comAvita Medical (NASDAQ:RCEL) Given New $14.00 Price Target at D. Boral CapitalSeptember 7, 2025 | americanbankingnews.com71,738 Shares in Avita Medical Inc. $RCEL Purchased by Nuveen LLCSeptember 6, 2025 | marketbeat.comBrokerages Set Avita Medical Inc. (NASDAQ:RCEL) Price Target at $12.40September 6, 2025 | americanbankingnews.comAvita Medical says data shows hospital stay reduction with RCELL SystemSeptember 4, 2025 | msn.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmSeptember 4, 2025 | globenewswire.comAvita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from AnalystsSeptember 4, 2025 | marketbeat.comAVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationSeptember 3, 2025 | globenewswire.comSecurities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Continues – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 3, 2025 | globenewswire.comWellington Management Group LLP Acquires Shares of 82,206 Avita Medical Inc. $RCELSeptember 3, 2025 | marketbeat.comAvita Medical (NASDAQ:RCEL) Director Robert Mcnamara Purchases 10,000 SharesAugust 30, 2025 | insidertrades.comAVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law FirmAugust 28, 2025 | globenewswire.comAVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the FirmAugust 27, 2025 | globenewswire.comAVITA Medical: Green Shoots Peaking Out From Hard ClayAugust 26, 2025 | seekingalpha.comKirby McInerney LLP Announces Investigation Against AVITA Medical, Inc. on Behalf of InvestorsAugust 22, 2025 | globenewswire.comINVESTOR ALERT: Investigation of AVITA Medical, Inc. (RCEL) Announced by Holzer & Holzer, LLCAugust 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTake Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025Buffett’s Wisdom Could Spell Trouble for Palantir ShortsBy Chris Markoch | August 26, 2025DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceBy Ryan Hasson | August 19, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025Royal Caribbean Earnings Beat Fuels Strong 2025 OutlookBy Jeffrey Neal Johnson | August 22, 2025AKLI, LUCD, PROF, and RCEL Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Lucid Diagnostics NASDAQ:LUCD$1.03 -0.04 (-3.74%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.06 +0.03 (+3.40%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Profound Medical NASDAQ:PROF$4.04 +0.08 (+2.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.02 -0.02 (-0.50%) As of 09/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.Avita Medical NASDAQ:RCEL$4.56 +0.18 (+4.11%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$4.55 -0.01 (-0.22%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
